PROFIL URINALISIS PENGGUNAAN IMUNAX PADA PASIEN DIABETES MELITUS (DM) RAWAT JALAN DI RSU PKU MUHAMMADIYAH BANTUL
Diabetes mellitus (DM) is a metabolic disease characterized by the onset of hyperglycemia due to secretion disorders, as well as resistance of insulin. Chronic hyperglycemic and other DM metabolic disorders will cause tissue and organ damage, such as the eyes, kidneys and vascular system. Some studi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin
2018-03-01
|
| Series: | JIIS: Jurnal Ilmiah Ibnu Sina |
| Subjects: | |
| Online Access: | http://jiis.akfar-isfibjm.ac.id/index.php/JIIS/article/view/138/133 |
| _version_ | 1811332512109035520 |
|---|---|
| author | Adnan Lolita |
| author_facet | Adnan Lolita |
| author_sort | Adnan |
| collection | DOAJ |
| description | Diabetes mellitus (DM) is a metabolic disease characterized by the onset of hyperglycemia due to secretion disorders, as well as resistance of insulin. Chronic hyperglycemic and other DM metabolic disorders will cause tissue and organ damage, such as the eyes, kidneys and vascular system. Some studies show that immunax (MBJH: minyak biji jinten hitam) has antidibetic benefits. This study aims to determine the description of urinalysis and proteinuria in DM patients who get immunax.
The study design was randomized controlled trial. MBJH is given in 2 dosage levels, 2x1 soft capsule and 2x2 soft capsul given for 20 days on the subject. Urine data taken before and after administration of immunax preparations.
The results showed that based on sex, age, education, occupation, marital status and the type of therapy used there was no significant difference in the characteristics and types of therapy used by the study subjects (patients at risk of metabolic syndrome) between the treatment groups and the placebo group. The result of urinalysis test showed that there was no difference of urinalysis image in the three groups.
The conclusion of this study was that there was no significant effect (p value> 0,05) on immunax (MBJH) on the urinalysis profile in patients with metabolic syndrome risk, both dose 2x1, 2x2, and control group |
| first_indexed | 2024-04-13T16:38:00Z |
| format | Article |
| id | doaj.art-5d4dbbdb807b4be6b9855c1942e9c560 |
| institution | Directory Open Access Journal |
| issn | 2502-647X 2503-1902 |
| language | English |
| last_indexed | 2024-04-13T16:38:00Z |
| publishDate | 2018-03-01 |
| publisher | Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin |
| record_format | Article |
| series | JIIS: Jurnal Ilmiah Ibnu Sina |
| spelling | doaj.art-5d4dbbdb807b4be6b9855c1942e9c5602022-12-22T02:39:22ZengSekolah Tinggi Ilmu Kesehatan ISFI BanjarmasinJIIS: Jurnal Ilmiah Ibnu Sina2502-647X2503-19022018-03-0131160167PROFIL URINALISIS PENGGUNAAN IMUNAX PADA PASIEN DIABETES MELITUS (DM) RAWAT JALAN DI RSU PKU MUHAMMADIYAH BANTULAdnan0Lolita1Fakultas Farmasi Universitas Ahmad DahlanFakultas Farmasi Universitas Ahmad DahlanDiabetes mellitus (DM) is a metabolic disease characterized by the onset of hyperglycemia due to secretion disorders, as well as resistance of insulin. Chronic hyperglycemic and other DM metabolic disorders will cause tissue and organ damage, such as the eyes, kidneys and vascular system. Some studies show that immunax (MBJH: minyak biji jinten hitam) has antidibetic benefits. This study aims to determine the description of urinalysis and proteinuria in DM patients who get immunax. The study design was randomized controlled trial. MBJH is given in 2 dosage levels, 2x1 soft capsule and 2x2 soft capsul given for 20 days on the subject. Urine data taken before and after administration of immunax preparations. The results showed that based on sex, age, education, occupation, marital status and the type of therapy used there was no significant difference in the characteristics and types of therapy used by the study subjects (patients at risk of metabolic syndrome) between the treatment groups and the placebo group. The result of urinalysis test showed that there was no difference of urinalysis image in the three groups. The conclusion of this study was that there was no significant effect (p value> 0,05) on immunax (MBJH) on the urinalysis profile in patients with metabolic syndrome risk, both dose 2x1, 2x2, and control grouphttp://jiis.akfar-isfibjm.ac.id/index.php/JIIS/article/view/138/133DMimmunaxMBJHproteinuria |
| spellingShingle | Adnan Lolita PROFIL URINALISIS PENGGUNAAN IMUNAX PADA PASIEN DIABETES MELITUS (DM) RAWAT JALAN DI RSU PKU MUHAMMADIYAH BANTUL JIIS: Jurnal Ilmiah Ibnu Sina DM immunax MBJH proteinuria |
| title | PROFIL URINALISIS PENGGUNAAN IMUNAX PADA PASIEN DIABETES MELITUS (DM) RAWAT JALAN DI RSU PKU MUHAMMADIYAH BANTUL |
| title_full | PROFIL URINALISIS PENGGUNAAN IMUNAX PADA PASIEN DIABETES MELITUS (DM) RAWAT JALAN DI RSU PKU MUHAMMADIYAH BANTUL |
| title_fullStr | PROFIL URINALISIS PENGGUNAAN IMUNAX PADA PASIEN DIABETES MELITUS (DM) RAWAT JALAN DI RSU PKU MUHAMMADIYAH BANTUL |
| title_full_unstemmed | PROFIL URINALISIS PENGGUNAAN IMUNAX PADA PASIEN DIABETES MELITUS (DM) RAWAT JALAN DI RSU PKU MUHAMMADIYAH BANTUL |
| title_short | PROFIL URINALISIS PENGGUNAAN IMUNAX PADA PASIEN DIABETES MELITUS (DM) RAWAT JALAN DI RSU PKU MUHAMMADIYAH BANTUL |
| title_sort | profil urinalisis penggunaan imunax pada pasien diabetes melitus dm rawat jalan di rsu pku muhammadiyah bantul |
| topic | DM immunax MBJH proteinuria |
| url | http://jiis.akfar-isfibjm.ac.id/index.php/JIIS/article/view/138/133 |
| work_keys_str_mv | AT adnan profilurinalisispenggunaanimunaxpadapasiendiabetesmelitusdmrawatjalandirsupkumuhammadiyahbantul AT lolita profilurinalisispenggunaanimunaxpadapasiendiabetesmelitusdmrawatjalandirsupkumuhammadiyahbantul |